Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 9/20 | 0.36 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | CES2 | O00748 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 2/20 | 0.34 |
| ▸ | ARG2 | P78540 | 2/20 | 0.34 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3708678 | 1.00 | MLYCD (0.36) | MLYCDFAAHCES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL3708677 | 1.00 | MLYCD (0.36) | MLYCDFAAHCES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL29024974 | 0.97 | MLYCD (0.35) | MLYCDFAAHCES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL6534847 | 0.95 | MLYCD (0.34) | MLYCDFAAHCES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL7929496 | 0.95 | MLYCD (0.34) | MLYCDFAAHCES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL9293783 | 0.89 | MLYCD (0.34) | MLYCDFAAHARG1ARG2PPIP5K2 | |
| Trifluoroacetic Acid SCHEMBL6534970 | 0.87 | FAAH (0.47) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL1432240 | 0.85 | TDP1 (0.44) | MLYCDFAAHMEN1CYP1A2KMT2A | |
| Trifluoroacetic Acid SCHEMBL28455031 | 0.85 | PPIP5K2 (0.38) | MLYCDPPIP5K2 | |
| Trifluoroacetic Acid SCHEMBL17396033 | 0.83 | CHRM2 (0.38) | MLYCDFAAHCES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110922582-B | Perfluoro polyether siloxane compound and preparation method and application thereof | 东莞东阳光科研发有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-109897176-B | Perfluoropolyether siloxane compound and synthesis method and application thereof | 乳源东阳光氟有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-115141257-A | Purification method of degarelix | 浙江苏泊尔制药有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-111393253-A | Synthesis method of compound containing trans-substituted cyclohexyl | 江苏广域化学有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-110922582-A | Perfluoropolyether siloxane compound and preparation method and application thereof | 东莞东阳光科研发有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-109897176-A | A kind of perfluoropolyether silicone compounds and its synthetic method and application | 乳源东阳光氟有限公司 | 2019-06-18 | — | — | CN | claimed |
| EP-1861364-B1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | C P PHARMACEUTICALS INTERNAT C V (US) | 2011-05-11 | — | — | EP | claimed |
| US-7709169-B2 | Charge trapping releaser containing charge transport layer photoconductors | XEROX CORPORATION (US) | 2010-05-04 | — | — | US | claimed |
| US-7687212-B2 | Charge trapping releaser containing photogenerating layer photoconductors | XEROX CORPORATION (US) | 2010-03-30 | — | — | US | claimed |
| US-20090092909-A1 | CHARGE TRAPPING RELEASER CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| US-20090092908-A1 | CHARGE TRAPPING RELEASER CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| JP-2008533128-A | — | — | 2008-08-21 | — | — | JP | claimed |
| EP-1861364-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | Pfizer Science and Technology Ireland Limited (IE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097909-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) | 2006-09-21 | — | — | WO | claimed |
| US-20050196789-A1 | Preparation of biologically derived fluids for biomarker determination by mass spectrometry | APPLERA CORPORATION (US) | 2005-09-08 | — | — | US | claimed |
| EP-4320138-B1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260062375-A1 | AMINE SEPARATION METHOD | DAICEL CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| US-4386026-A | Cell-specific glycopeptide ligands | MERCK & CO., INC. (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0063373-A1 | Cell-specific glycopeptide ligands | MERCK & CO. INC. (US) | 1982-10-27 | — | — | EP | disclosed |
| US-3944538-A | Process and apparatus for the synthesis of peptides not linked to polymers | BODANSZKY MIKLOS | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062375-A1 | AMINE SEPARATION METHOD | SLC7A1, SAMM50, PNMT | MLYCD 4671/4885FAAH 1434/4885CES1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.